First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

by Anne-Claire Hardy-Bessard, Fabien Brocard, Florian Clatot, Alain Lortholary, Benoît You, Julien Grenier, Jérôme Martin-Babau, Brigitte Lucas, Jérôme Meunier, Jean-Marc Ferrero, Aude-Marie Savoye, Adina Marti, Raymond Despax, Isabelle Moullet, George Emile
Published 2020-12-01